ACA, healthcare legislation hot topics at AHA meeting

The 2017 meeting of the American Hospital Association (AHA) led off with an unsurprising topic: the legislation to repeal and replace the Affordable Care Act (ACA).  

The American Health Care Act (AHCA) was opposed by the AHA (along with many major medical associations), but it managed to pass the House of Representatives with one vote to spare the week prior to the meetings. In his May 8 remarks at the meeting, AHA President and CEO Rick Pollack called on the U.S. Senate to “reset” the discussion on the bill, arguing the version which passed the House would jeopardize the coverage gains made under the ACA.

“We believe that any legislation must be viewed through this lens—and carefully evaluated regarding its impact on both individuals and the ability of hospitals and health systems to care for all who walk through our doors,” Pollack said, according to a copy of his prepared remarks provided to HealthExec.

Among the provisions singled out by Pollack were protections for patients with pre-existing conditions. While the legislation maintains the ACA’s ban on insurers denying coverage based on medical history, states could waive requirements and allow the return of medical underwriting for individual customers, potentially pricing those with chronic conditions out of the individual market.

He also took issue with how the legislation would affect Medicaid—$839 billion would be cut from the program over the course of a decade, rolling back much of the program’s expansion under the ACA. While Pollack expressed concern about this loss of coverage, he also said the bill wouldn’t restore all of the lost disproportionate share hospital (DSH) payments the ACA took away, leaving hospitals on the hook for the expected rise in uncompensated care.

“If coverage is not maintained at the current level, those resources need to be returned to hospitals and health systems in order to provide services to what will likely be an increased number of uninsured Americans,” he said.

His remarks weren’t free of criticism of the ACA, noting the association has advocated for specific tweaks to the law. The AHCA doesn’t follow its recommendations for improvement, so Pollack said they’ll be pressuring for changes in the Senate, where the Republican majority is smaller and largely believed to be more moderate.

“The House bill is not consistent with our deeply held principles of providing coverage for those who need it and ensuring that the most vulnerable are not left behind,” he said. “That’s why the Senate must reject the House bill as a starting point.”

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.